'A risk-based approach does not necessarily mean less testing. It means decisions are based on sound science and a risk-based control strategy.'

摘要

A number of Indian companies are already making their move. Ranbaxy (Gurgaon) acquired Terapia S.A., Romania's largest independent pharma-ceuticals company, for dollar324 million in 2006. Sun Pharma (Mumbai) bought ICN Hungary, a producer of controlled substance APIs in 2005. And, Strides Arcolab (Bangalore), a leading Indian specialist in the production of finished generic medicines, has established a regional production base for making dosage-form pharmaceuticals in Warsaw, Poland, which will also be part of the company's global manufacturing network.